In patients with symptomatic severe aortic stenosis at intermediate or higher surgical risk, CoreValve or Evolut transcatheter aortic valve implantation (TAVI) was associated with a lower 5-year ...
Women had better self-care at 5 years with self-expanding valves, raising questions about lower gradients and stroke impacts.
After receiving a green light earlier this year from the FDA, Medtronic has now collected a European approval for the latest version of its transcatheter aortic valve replacement implant. Compared to ...
PARIS, France—Fluoroscopy times and the amount of contrast needed during coronary angiography are significantly higher in patients with a prior TAVI, with the self-expanding transcatheter heart valves ...
Medtronic Plc (NYSE: MDT) has announced the complete two-year outcomes from a low-risk trial comparing the Evolut transcatheter aortic valve replacement (TAVR) system to open-heart surgery in ...
Hosted on MSN
Early signs of valve failure one year after transcatheter aortic valve implantation identified
A new study published in The Annals of Thoracic Surgery, has identified early hemodynamic valve deterioration (HVD) in more than 6% of patients just one year after undergoing transcatheter aortic ...
Clinical suitability is the primary requirement for selection of a patient for TAVI. Although TAVI compares favorably to conservative treatment in patients at high risk of or inoperable by ...
Medtronic is pumping up its activation of heart valve disease patients. The company has partnered with an advocacy group for heart valve disease, Heart-Valve-Surgery.com, to create a digital platform ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results